Among active 13F managers last quarter, 1 opened and 1 added, while 1 reduced; the largest holder to move was Ikarian Capital, LLC (+196%). Over the last 180 days, 2 insiders bought and none sold, a net +$44K in open-market trades.
Funds lean in and no leg opposes.
10 tracked 13F filers disclose a position in CNSP as of the latest SEC 13F filings, a combined $1000K in reported value. Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| # | Fund | Shares | Position value | Last move | As of | History |
|---|---|---|---|---|---|---|
| 1 | Ikarian Capital, LLC | 136K | $649K | ▲+196% Added · +90K sh | Q2 2026 | |
| 2 | Stonepine Capital Management, LLC | 42K | $199K | ▼−32% Reduced · −19K sh | Q2 2026 | |
| 3 | Boothbay Fund Management, LLC | 14K | $65K | —Held | Q2 2026 | |
| 4 | Vanguard Fiduciary Trust Co | 10K | $49K | ▲New +10K sh | Q2 2026 | |
| 5 | Vanguard Capital Management LLC | 7K | $33K | ▲New +7K sh | Q2 2026 | |
| 6 | Tower Research Capital LLC (TRC) | 1K | $3K | ▲New +1K sh | Q1 2026 | |
| 7 | UBS Group AG | 729 | $2K | ▲+19% Added · +118 sh | Q1 2026 | |
| 8 | Barrett & Company, Inc. | 8 | $38 | —Held | Q2 2026 | |
| 9 | Danske Bank A/s | 1 | $5 | —Held | Q2 2026 | |
| 10 | Citigroup Inc | 1 | $2 | ▲New +1 sh | Q1 2026 |
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
Last quarter, 1 fund opened a new position in CNSP and 1 added to an existing one, while 1 reduced. Based on 13F filings from active, signal-eligible managers (passive index funds and other mechanical holders are excluded from this count).
| Company | Co-held by | Their position there |
|---|---|---|
| Tenax Therapeutics IncTENX | 4 funds | $25.6M |
| Verastem IncVSTM | 4 funds | $13.9M |
| Ultragenyx Pharmaceutical InRARE | 4 funds | $11.8M |
| Spruce Biosciences IncSPRB | 4 funds | $10.4M |
| Bioage Labs IncBIOA | 4 funds | $6.9M |
| Cabaletta Bio IncCABA | 4 funds | $5.6M |
| Rein Therapeutics IncRNTX | 4 funds | $4.2M |
| Arvinas IncARVN | 4 funds | $4.2M |
| Cybin IncHELP | 4 funds | $2.0M |
| Kalaris Therapeutics IncKLRS | 4 funds | $2.0M |
| Pliant Therapeutics IncPLRX | 4 funds | $1.8M |
| PMV Pharmaceuticals IncPMVP | 4 funds | $876K |
Ranked by how many of CNSP's tracked holders also hold each name. The last column is those co-holders' combined reported position in that name, not in CNSP.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| May 18, 2026 | Fisher Michal | Director | Buy (P) | 2K | $10K |
| May 18, 2026 | Charles Faith L. | Director | Buy (P) | 7K | $34K |
| Feb 1, 2024 | Climaco John M | Chief Executive Officer, Director | Buy (P) | 167K | $50K |
| Feb 1, 2024 | Downs Christopher | Chief Financial Officer | Buy (P) | 67K | $20K |
| Feb 1, 2024 | Evans Carl Anthony | Director | Buy (P) | 33K | $10K |
| Feb 1, 2024 | Gumulka Jerzy | Director | Buy (P) | 33K | $10K |
| Aug 22, 2023 | Downs Christopher | Chief Financial Officer | Buy (P) | 27K | $34K |
| Aug 16, 2023 | Climaco John M | Chief Executive Officer, Director | Buy (P) | 3K | $5K |
| Apr 19, 2023 | Gumulka Jerzy | Director | Buy (P) | 3K | $4K |
| Apr 17, 2023 | Downs Christopher | Chief Financial Officer | Buy (P) | 3K | $10K |
| Apr 12, 2023 | Climaco John M | Chief Executive Officer, Director | Buy (P) | 15K | $10K |
| Apr 10, 2023 | Gumulka Jerzy | Director | Buy (P) | 7K | $5K |
Where institutional funds (13F), corporate insiders (Form 4) and US House members (STOCK Act) are buying or selling the same name in the same window. Green is buying, red is selling.
Insiders and Congress: last 180 days. Funds: latest 13F, top 100 holders incl. passive
| Source | Buying | Selling | Net |
|---|---|---|---|
13F funds Top 100 holders by value, passive included; the hero counts active managers only | 2 | 1 | – |
Insiders Form 4 open-market | 2 | 0 | +$44K |
US House STOCK Act trades | 0 | 0 | $0 |
Capital Rotation reports where institutional capital disclosed rotating, as of the latest public SEC 13F filings. It is data, not investment advice, a recommendation, or a prediction. Filings lag about 45 days and cover long US equity positions only. Past disclosed flows do not indicate future prices. Do your own research; consult a licensed advisor.
Connected entities for CNSP
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/CNSP/capital-change-brief"
Use Arkolith's capital_change_brief for CNSP. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for CNSP. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes.